Week of October 12th, 2020 | Vol. 9, Issue 41 |
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
Project Montage
Strategic Advisory | Generic Pharma + CDMO | Exploring full range of transaction alternatives
Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization
Project Athena
Sell-side | Medical Device | Novel medical device for the treatment of pelvic organ prolapse
Project Olympus
Sell-side | Pharma | Portfolio of generic injectable products
|
|
Bristol Myers Squibb (BMS) and MyoKardia have entered a merger agreement under which BMS will acquire MyoKardia for $13.1 billion. The transaction was unanimously approved by both the BMS and
MyoKardia boards and is anticipated to close during the fourth quarter of 2020.
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through the transaction, BMS gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (HCM), a chronic heart disease with high morbidity and patient impact. A New Drug Application (NDA) for mavacamten for the treatment of symptomatic obstructive HCM—based on data from the EXPLORER-HCM study—is expected to be submitted to the U.S. FDA in the first quarter of 2021.
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
15 transactions totaling $14,404 million
Supplies, Equipment & Services
24 transactions totaling $3,150 million
Healthcare IT & Managed Care
5 transactions totaling $44 million
Healthcare Facilities & Distributors
11 transactions totaling $52 million
|
|
Pharma & Biotech
21 transactions totaling $553 million
Supplies, Equipment & Services
20 transactions totaling $252 million
Healthcare IT & Managed Care
18 transactions totaling $163 million
Healthcare Facilities & Distributors
4 transactions totaling $5 million
|
|
Pharma & Biotech
22 transactions totaling $47,279 million
Supplies, Equipment & Services
7 transactions totaling $1,999 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
2 transactions totaling $475 million
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
October 8, 2020 - Fierce Biotech
As Arrowhead continues its turnaround, this election cycle is looking like a new era compared to the last as it strikes a major billion-dollar deal with Takeda.
The new pact revolves around a collab and license deal for ARO-AAT, a phase 2 investigational RNA interference (RNAi) therapy designed to treat alpha-1 antitrypsin-associated liver disease (AATLD).
October 6, 2020 - Fierce Pharma
Battling more than 20,000 lawsuits alleging its talc powder causes cancer, Johnson & Johnson is moving to settle more than 1,000 suits for about $100 million, Bloomberg reports. J&J, which hasn’t faced a talc trial in months amid the pandemic, used the slowdown to advance settlement negotiations, according to the news service. The company is inking settlements with numerous law firms representing more than 1,000 clients, the report said.
October 6, 2020 - Fierce Pharma
After years of proxy squabbles and FDA scrutiny of a key drug, troubled AMAG Pharmaceuticals appeared to be in the clear with a buyout deal signed last week. But the FDA decided to drop the hammer on one of AMAG's drugs, and it could endanger the drugmaker's acquisition.
October 5, 2020 - Fierce Pharma
After a jury in 2017 ordered Teva to pay $235 million for patent infringement of a GlaxoSmithKline heart drug, the generics giant convinced a district judge to nix the verdict. But now, its fortunes have changed again.
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
